Compare NCLH & RVTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCLH | RVTY |
|---|---|---|
| Founded | 1966 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 11.7B |
| IPO Year | 2013 | N/A |
| Metric | NCLH | RVTY |
|---|---|---|
| Price | $22.96 | $115.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | $28.44 | ★ $113.46 |
| AVG Volume (30 Days) | ★ 15.1M | 1.2M |
| Earning Date | 02-26-2026 | 02-02-2026 |
| Dividend Yield | N/A | ★ 0.25% |
| EPS Growth | ★ 11.76 | N/A |
| EPS | 1.40 | ★ 1.99 |
| Revenue | ★ $9,692,558,000.00 | $2,813,367,000.00 |
| Revenue This Year | $6.84 | $5.30 |
| Revenue Next Year | $10.12 | $3.03 |
| P/E Ratio | ★ $16.52 | $57.20 |
| Revenue Growth | ★ 3.59 | 3.37 |
| 52 Week Low | $14.21 | $81.36 |
| 52 Week High | $29.29 | $128.29 |
| Indicator | NCLH | RVTY |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 75.52 |
| Support Level | $22.65 | $100.98 |
| Resistance Level | $24.79 | $115.00 |
| Average True Range (ATR) | 0.82 | 3.53 |
| MACD | -0.12 | 1.55 |
| Stochastic Oscillator | 28.59 | 98.19 |
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.